^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    Related drugs:
    7d
    PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel (clinicaltrials.gov)
    P1, N=40, Completed, International Partnership for Microbicides, Inc. | Phase classification: P1/2 --> P1
    Phase classification
    14d
    DORDOL: Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (clinicaltrials.gov)
    P3, N=150, Recruiting, Chelsea and Westminster NHS Foundation Trust | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NEFL (Neurofilament Light Chain)
    20d
    Efavirenz for the Treatment of Creutzfeldt-Jakob Disease (clinicaltrials.gov)
    P3, N=246, Not yet recruiting, Xuanwu Hospital, Beijing
    New P3 trial
    |
    efavirenz
    22d
    "TACKITON: The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY (clinicaltrials.gov)
    P=N/A, N=26, Recruiting, University of Toronto | Trial completion date: Sep 2026 --> Nov 2028 | Trial primary completion date: Jan 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    efavirenz
    26d
    A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Janssen Sciences Ireland UC | Trial primary completion date: Jun 2027 --> Aug 2026
    Trial primary completion date
    1m
    CROWN: A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (clinicaltrials.gov)
    P3, N=332, Recruiting, ViiV Healthcare | Trial primary completion date: Dec 2026 --> Aug 2026
    Trial primary completion date • Head-to-Head
    1m
    TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (clinicaltrials.gov)
    P3, N=180, Active, not recruiting, Janssen Sciences Ireland UC | Trial completion date: Jan 2032 --> Apr 2026
    Trial completion date
    2ms
    IMAdART: Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (clinicaltrials.gov)
    P=N/A, N=90, Completed, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Trial completion date: Jul 2025 --> Feb 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    2ms
    DoraDO: Doravirine Dose Optimisation in Pregnancy (clinicaltrials.gov)
    P4, N=76, Recruiting, University of Liverpool | Trial completion date: Feb 2026 --> Jul 2028 | Trial primary completion date: Nov 2025 --> Jul 2028
    Trial completion date • Trial primary completion date
    2ms
    Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (clinicaltrials.gov)
    P2, N=84, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Mar 2028 --> Nov 2028
    Trial primary completion date
    2ms
    Randomized Multicentric Proof-of-Concept Phase 2 Trial Doravirine in the Early Outpatient Management of nWest Nile Virus Infection in Patients at Risk of Progression - DORICO Trial (2025-521677-14-00)
    P1/2, N=50, Not yet recruiting, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
    New P1/2 trial
    2ms
    Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. (PubMed, J Antimicrob Chemother)
    A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor-based regimens.
    Clinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)